

NMI Antibody (N-term)

Affinity Purified Rabbit Polyclonal Antibody (Pab) Catalog # AP19351a

Specification

NMI Antibody (N-term) - Product Information

WB,E Application **Primary Accession** 013287 Other Accession NP 004679.2 Reactivity Human Host **Rabbit** Clonality **Polyclonal** Isotype Rabbit IgG Calculated MW 35057 Antigen Region 1-30

NMI Antibody (N-term) - Additional Information

Gene ID 9111

Other Names

N-myc-interactor, Nmi, N-myc and STAT interactor, NMI

Target/Specificity

This NMI antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 1-30 amino acids from the N-terminal region of human NMI.

Dilution

WB~~1:1000

E~~Use at an assay dependent concentration.

Format

Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.

Storage

Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.

Precautions

NMI Antibody (N-term) is for research use only and not for use in diagnostic or therapeutic procedures.

NMI Antibody (N-term) - Protein Information

Name NMI (HGNC:7854)

Function Acts as a signaling pathway regulator involved in innate immune system response



(PubMed: 26342464, PubMed: 29038465, PubMed: 29350881, PubMed: 9989503). In response to interleukin 2/IL2 and interferon IFN-gamma/IFNG, interacts with signal transducer and activator of transcription/STAT which activate the transcription of downstream genes involved in a multitude of signals for development and homeostasis (PubMed:29377960, PubMed:9989503). Enhances the recruitment of CBP/p300 coactivators to STAT1 and STAT5, resulting in increased STAT1- and STAT5-dependent transcription (PubMed: 9989503). In response to interferon IFN-alpha, associates in a complex with signaling pathway regulator IFI35 to regulate immune response; the complex formation prevents proteasome-mediated degradation of IFI35 (PubMed: 10779520, PubMed: 10950963). In complex with IFI35, inhibits virus-triggered type I IFN-beta production when ubiquitinated by ubiquitin-protein ligase TRIM21 (PubMed: 26342464). In complex with IFI35, negatively regulates nuclear factor NF-kappa-B signaling by inhibiting the nuclear translocation, activation and transcription of NF-kappa-B subunit p65/RELA, resulting in the inhibition of endothelial cell proliferation, migration and re-endothelialization of injured arteries (PubMed: <u>29350881</u>). Negatively regulates virus-triggered type I interferon/IFN production by inducing proteosome-dependent degradation of IRF7, a transcriptional regulator of type I IFN, thereby interfering with cellular antiviral responses (By similarity). Beside its role as an

intracellular signaling pathway regulator, also functions extracellularly as damage-associated molecular patterns (DAMPs) to promote inflammation, when actively released by macrophage to the extracellular space during cell injury or pathogen invasion (PubMed:29038465). Macrophage-secreted NMI activates NF-kappa-B signaling in adjacent macrophages through Toll-like receptor 4/TLR4 binding and activation, thereby inducing NF-kappa-B translocation from the cytoplasm into the nucleus which promotes the release of pro- inflammatory cytokines (PubMed:29038465).

Cellular Location

Cytoplasm. Nucleus. Secreted Note=Cytoplasmic NMI localizes in punctate granular structures (PubMed:10950963, PubMed:9781816). Nuclear localization increased following IFN-alpha treatment (PubMed:10950963, PubMed:9781816) Extracelullar following secretion by macrophage (PubMed:29038465)

Tissue Location

Expressed in adult spleen, liver, and kidney (PubMed:9781816). Expressed in fetal thymus, liver, placenta, spleen, lung, and kidney but not brain (PubMed:9781816). Expressed in macrophages (PubMed:29038465).


NMI Antibody (N-term) - Protocols

Provided below are standard protocols that you may find useful for product applications.

- Western Blot
- Blocking Peptides
- Dot Blot
- Immunohistochemistry
- Immunofluorescence
- <u>Immunoprecipitation</u>
- Flow Cytomety
- Cell Culture

NMI Antibody (N-term) - Images





NMI Antibody (N-term)(Cat. #AP19351a) western blot analysis in WiDr cell line lysates (35ug/lane). This demonstrates the NMI antibody detected the NMI protein (arrow).

NMI Antibody (N-term) - Background

NMYC interactor (NMI) encodes a protein that interacts with NMYC and CMYC (two members of the oncogene Myc family), and other transcription factors containing a Zip, HLH, or HLH-Zip motif. The NMI protein also interacts with all STATs except STAT2 and augments STAT-mediated transcription in response to cytokines IL2 and IFN-gamma. The NMI mRNA has low expression levels in all human fetal and adult tissues tested except brain and has high expression in cancer cell line-myeloid leukemias. [provided by RefSeq].

NMI Antibody (N-term) - References

Davila, S., et al. Genes Immun. 11(3):232-238(2010) Fillmore, R.A., et al. Int. J. Cancer 125(3):556-564(2009) Quaye, L., et al. Br. J. Cancer 100(6):993-1001(2009) Vega, A., et al. Gynecol. Oncol. 112(1):210-214(2009) Quaye, L., et al. Clin. Cancer Res. 14(18):5833-5839(2008)